First-Line Immune Checkpoint Inhibitor-Based Sequential Therapies for Advanced Hepatocellular Carcinoma: Rationale for Future Trials
Giuseppe Cabibbo(Azienda Ospedaliera Universitaria Policlinico "Paolo Giaccone" di Palermo), Calogero Cammà(Department of Health), Ferràn Torres(Evidence (Italy)), Vincenza Calvaruso(University of Palermo), Ciro Celsa(Department of Health), V. Di Marco(University of Palermo), Giacomo Emanuele Maria Rizzo(University of Palermo), Salvatore Battaglia(University of Palermo), Salvatore Petta(University of Palermo), Jordi Bruix(Hospital Clínic de Barcelona), María Reig(Hospital Clínic de Barcelona), Marco Enea(University of Palermo), Antonio Craxı̀(University of Palermo), Amit G. Singal(Southwestern Medical Center)
Cited by 50
Related Papers
Management of Hepatocellular Carcinoma: An Update Δσ
|Hepatology|2011|8.1k
Management of Hepatocellular Carcinoma *
|Hepatology|2005|5.9k
Clinical Management of Hepatocellular Carcinoma. Conclusions of the Barcelona-2000 EASL Conference
|Journal of Hepatology|2001|4.1k
Evidence-Based Diagnosis, Staging, and Treatment of Patients With Hepatocellular Carcinoma
|Gastroenterology|2016|1.8k
Design and Endpoints of Clinical Trials in Hepatocellular Carcinoma
|JNCI Journal of the National Cancer Institute|2008|1.7k